Clinical Trials Using Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-CD20 Monoclonal Antibody-Interferon-alpha Fusion Protein IGN002. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • A Study of IGN002 for Refractory NHL

    This is a Phase 1 multi-center, open-label study that allows subjects who derived clinical benefit after completing IGN002 treatment in the Spectrum sponsored IGN002-101 study to continue treatment with IGN002. Subjects who completed the IGN002-101 study, tolerated IGN002 treatment, and did not experience progressive disease (PD) are eligible to participate in this study.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

    A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (NHL)
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California